Vyome Holdings, Inc — Form 8-K
Filed August 25, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 62/100
What the filing says
Vyome (market cap ~$6.4M) reported Q2 2026 cash of $7.9M (vs. $5.0M at Dec 31, 2025), stockholders' equity of $7.3M, and Q2 net loss of $720K ($0.10/share). The company advanced lead program VT-1953 with Phase 2 data showing statistically significant improvements in malodor and lesion pain; received FDA written response to March 2026 pre-IND briefing and plans Type C meeting. Signed in-license agreement with Impetis Biosciences for two JAK inhibitor assets targeting autoimmune/inflammatory conditions. Company maintains zero debt and no toxic financing.
Why this rating
Clinical milestone (Phase 2 data, FDA engagement) + pipeline expansion (Impetis deal) + cash improvement ($3.9M raised, 78% increase) material to tiny $6.4M market cap; runway extended. Lead asset still early-stage; execution risk remains high.
See more from August 25, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.